Sangamo Therapeutics (SGMO) Misses Q1 EPS by 16c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil rally pressures S&P, Nasdaq; Microsoft, Salesforce buoy Dow
- Oil prices rise 2% as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Lumentum shares fall after hitting 52-week high
- Getty Images to go private via prepackaged Chapter 11 restructuring
Sangamo Therapeutics Reports First Quarter 2019 Financial Results
May 8, 2019 4:01 PM EDTBRISBANE, Calif., May 8, 2019 /PRNewswire/ --Â Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported first quarter 2019 financial results and recent business highlights.
"With recent encouraging clinical data in hemophilia A gene therapy and ex vivo gene-edited cell therapy for beta... More



